{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:21:16Z","timestamp":1773800476471,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.canrad.2018.06.003","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T08:11:10Z","timestamp":1533370270000},"page":"492-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Nouveaut\u00e9s dans la prise en charge des carcinomes nasopharyng\u00e9s"],"prefix":"10.1016","volume":"22","author":[{"given":"P.","family":"Blanchard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Moya-Plana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Pignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Even","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bidault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Temam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ruffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2018.06.003_bib0130","unstructured":"GLOBOCAN 2012\u00a0n.d. http:\/\/globocan.iarc.fr\/old\/summary_table_pop_prev.asp?selection=66250&title=France+%28metropolitan%29&sex=0&window=1&sort=0&submit=%C2\u00a0%A0Execute%C2\u00a0%A0 (accessed May 28, 2018)."},{"key":"10.1016\/j.canrad.2018.06.003_bib0135","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.ejca.2015.08.006","article-title":"Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up","volume":"51","author":"Zhang","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2018.06.003_bib0140","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0145","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0150","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","article-title":"What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis","volume":"35","author":"Ribassin-Majed","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0155","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0160","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/annonc\/mdx770","article-title":"A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)","volume":"29","author":"Frikha","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0165","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/jnci\/djr432","article-title":"Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial","volume":"103","author":"Chen","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2018.06.003_bib0170","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2017.10.032","article-title":"International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma","volume":"126","author":"Lee","year":"2018","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2017.10.016","volume":"126","author":"Gr\u00e9goire","year":"2018","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0180","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.oraloncology.2014.01.017","article-title":"The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT","volume":"50","author":"Ng","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0185","first-page":"S104","article-title":"[Radiotherapy for nasopharyngeal carcinoma]","volume":"20","author":"Maingon","year":"2016","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0190","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijrobp.2017.09.038","article-title":"Facility volume and survival in nasopharyngeal carcinoma","volume":"100","author":"Yoshida","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.06.003_bib0195","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.virusres.2009.07.005","article-title":"The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal","volume":"143","author":"Chang","year":"2009","journal-title":"Virus Res"},{"key":"10.1016\/j.canrad.2018.06.003_bib0200","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1200\/JCO.2006.07.7982","article-title":"Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma","volume":"24","author":"Leung","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0205","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.06.003_bib0210","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.29413","article-title":"Clinical utility of plasma Epstein-Barr virus DNA and ERCC1\u00a0single nucleotide polymorphism in nasopharyngeal carcinoma","volume":"121","author":"Hui","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2018.06.003_bib0215","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.06.003_bib0220","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1200\/JCO.2017.35.15_suppl.6002","article-title":"A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT)","volume":"35","author":"Chan","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semradonc.2017.08.004","article-title":"Proton therapy for head and neck cancers","volume":"28","author":"Blanchard","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21037\/cco.2016.03.05","article-title":"Proton therapy for nasopharyngeal carcinoma","volume":"5","author":"Holliday","year":"2016","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.14338\/IJPT-15-00011.1","article-title":"Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: a case-match control study of intensity-modulated proton therapy and intensity-modulated photon therapy","volume":"2","author":"Holliday","year":"2015","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.canrad.2018.06.003_bib0240","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international multicenter study of the mayo clinic phase 2\u00a0consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0245","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2017.75.5165","article-title":"Prognostic model for stratification of radioresistant nasopharynx carcinoma to curative salvage radiotherapy","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.003_bib0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.oraloncology.2017.02.012","article-title":"Proposal for a new risk classification system for nasopharyngeal carcinoma patients with post-radiation nasopharyngeal necrosis","volume":"67","author":"Yang","year":"2017","journal-title":"Oral Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818301598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818301598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:29:51Z","timestamp":1761136191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321818301598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":25,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1278321818301598"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2018.06.003","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouveaut\u00e9s dans la prise en charge des carcinomes nasopharyng\u00e9s","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2018.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}